---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093946"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:46:32.484741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026

## Summary
- Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.
- Revenue from Gilead collaboration $8.5M in Q2 2024 (vs. $0 in Q2 2023); R&D expenses $16.3M (up from $12.5M).
- Net loss $11.2M ($1.98 per share) vs. $16.9M ($3.88) in Q2 2023; net loss improved on higher revenue.
- Phase 1a/b dosing initiated for ABI-5366 (genital herpes) and Phase 1b for ABI-4334 (chronic HBV infection).
- Two additional candidates (ABI-1179, ABI-6250) expected to enter clinic by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-093946
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/0000950170-24-093946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/asmb-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093946
- JSON: https://secwatch.observer/filing/0000950170-24-093946.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.